Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Apr 27, 2021

Provention Bio Provides Additional Regulatory Update on Biologics License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals
Apr 26, 2021

Sanofi to help manufacture Moderna COVID-19 vaccine, supporting global supply demands

- Sanofi is the only company to leverage its manufacturing capacity and expertise to support three different COVID-19 vaccines to support the global supply of vaccines and help address the pandemic
Apr 26, 2021

Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial

Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants.1-5
Apr 23, 2021

New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years

Nearly 30 data presentations at AAD and ESPD across clinical and real-world settings, including the impact of Dupixent on disease measures in uncontrolled moderate-to-severe atopic dermatitis
Apr 8, 2021

Provention Bio Provides Regulatory Update on Biologics License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals

- Conference call and webcast to be held today at 5:00 p.m. Eastern Time -

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.